Apollomics Inc's Customers Performance

Name: Apollomics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

APLM

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


APLM's Source of Revenues		During the corresponding time, Apollomics Inc While revenue at the Apollomics Inc 's corporate clients • List of APLM Customers

for the same period Apollomics Inc

• List of APLM Customers

Apollomics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Apollomics Inc's Comment on Sales, Marketing and Customers

News about Apollomics Inc Contracts

Observations on the Efficacy of Vebreltinib in Patients with Non-Small Cell Lung Cancer Exhibiting METex14 Skipping M...

In this esteemed publication, we take the liberty of presenting findings that emanated from a notable assembly, the European Society for Medical Oncology (ESMO) Congress of the year 2024, where Apollomics revealed significant data concerning Vebreltinib a novel therapeutic agent under examination for its utility in cases of non-small cell lung cancer (NSCLC) harbouring METex14 skipping mutations.Vebreltinib, it has been noted, exhibits a remarkable efficacy in the treatment of patients afflicted with NSCLC, specifically those possessing the METex14 skipping mutation. This effectiveness is observed both in individuals who have not previously undergone treatment (treatment naive) as well as in those who have...

Vebreltinibs Continued Efficacy and Safety for Treating Tumor Types Carrying MET-Driver Alterations: A Game-Changer ...

In recent years, precision medicine has revolutionized cancer treatment by targeting specific genetic alterations within tumors. Apollomics, a leading biopharmaceutical company, has taken a significant step forward in this field with the exciting data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data from Phase 2 and 2/3 trials have highlighted the continued efficacy and safety of their breakthrough drug, vebreltinib, in treating various tumor types carrying MET-driver alterations. This article aims to outline the facts presented in the studies and assess their impact on Apollomics.Continued Efficacy and Safety of Vebreltinib:The phase 2 and 2/3 trials conducted by A...

APLM's Stock Performance relative to it's Customers

APLM's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Apollomics Inc	0.00	8.50	-10.94	20
SUBTOTAL	0.00	0.00	0.00	-

Sources: Apollomics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Apollomics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Apollomics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.